Redirection of cellular immunity by protein tyrosine kinase...

Details Redirection of cellular immunity by protein tyrosine kinase... Redirection of cellular immunity by protein tyrosine kinase...

2008-01-22

2008-01-22

Wehbe, Anne M. (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093200, C424S093100, C435S325000, C435S366000, C435S372300, C435S455000, C435S320100

Reexamination Certificate

active

10151193

ABSTRACT:
Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5439819 (1995-08-01), Littman et al.
patent: 5504000 (1996-04-01), Littman et al.
patent: 5686281 (1997-11-01), Roberts
patent: 5712149 (1998-01-01), Roberts
patent: 6284240 (2001-09-01), Seed et al.
patent: 6410014 (2002-06-01), Seed et al.
patent: 0 180 878 (1986-05-01), None
patent: 0 314 317 (1989-05-01), None
patent: 0 325 262 (1989-07-01), None
patent: 0 340 793 (1989-11-01), None
patent: 0 394 827 (1990-10-01), None
patent: 10-63394 (1989-03-01), None
patent: 224379 (1990-12-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/01649 (1988-03-01), None
patent: WO 90/04640 (1990-05-01), None
patent: WO 90/11360 (1990-10-01), None
patent: WO 91/10736 (1991-07-01), None
patent: WO 92/10591 (1992-06-01), None
patent: WO 92/15322 (1992-09-01), None
patent: WO 93/19163 (1993-09-01), None
patent: WO 95/02686 (1995-01-01), None
patent: WO 95/21528 (1995-08-01), None
patent: WO 96/26265 (1996-08-01), None
Johnston et al. (1993) Science, vol. 260, 1286-1293.
Hoffenbach et al. (1989) J. Immunol., vol. 142(2), 452-462.
Fox (1994) Bio/Technology, vol. 12, 128.
Yamada et al. (1993) Eur. J. Biochem., vol. 213, 455-459.
Chen et al. (1998) Virology, vol. 246, 113-124.
LaBronte et al. (2002) J. Exp. Med., vol. 196(4) 431-445.
Abraham and Veillette, Mol. Cell. Biol. 10:5197-5206, 1990.
Accolla, J. Exp. Med., 157:1053-1058, 1983.
Al-Jaufy et al., Infection and Immunity, 62:956-960, 1994.
Alberola-Ila et al., J. Immunology 151(9):4423-4430, (Nov. 1, 1993).
Anderson et al., “CD3-negative Natural Killer Cells Express TCR as Part of a Novel Molecular Complex,” Nature 341:159-162, 1989.
Anderson et al., “Fc Receptor Type III (CD16) is Included in the NK Receptor Complex Expressed by Human Natural Killer Cells,” Proc. Natl. Acad. Sci. USA 87: 2274-2278, 1990.
Appleby et al., Cell 70:751-763, 1992.
Aruffo and Seed, EMBO J. 6:3313, 1987.
Aruffo et al., “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,” Proc. Natl. Acad. Sci. USA 84: 8573-8577, 1987.
Ashom et al., J. Virol. 64:2149 1990.
Aullo et al., EMBO J. 11:575-583, 1992.
Bachmann et al. “In vivo versus in vitro assays for assessment of T-and B-cell function” Current Opinion in Immunology, vol. 8 (2), 320-328, 1994.
Balk and Terhorst, Immunol. Ser. 45:411-416, 1989.
Baniyash et al., J. Biol. Chem. 263:9874-9878, 1988.
Bauer et al., Proc. Natl. Acad. Sci. USA 88:3842-3846, 1991.
Becker et al., “Expression of a Hybrid Immunoglobulin-T Cell Receptor Protein in Transgenic Mice,” Cell 58: 911-921, 1989.
Becker et al., “Messenger RNA in Cells Infected with Vaccinia Virus,” Biochemistry 51: 577-585, 1964.
Bell et al., Mol. Cell. Biol. 12:5548-5554, 1992.
Berke et al., “T Lymphocyte-Mediated Cytolysis—A Comprehensive Theory,” Mechanisms of Cell Mediated Cytotoxicity, 57-68, 1982.
Berke, “Lymphocyte-Triggered Internal Target Disintegration,” Immunology Today 12:396-399, 1991.
Berke, “Cytotoxic T-Lymphocytes; How Do They Function?,” Immunological Rev. 72:5-42, 1983.
Berkhout et al., “Transfection of Genes Encoding the T Cell Receptor-Associated CD3 complex into COS Cells Results in Assembly of the Macromolecular Structure.” Journal of Biological Chemsitry 263:8528-8536, 1988.
Blank et al., “Complete Structure and Expression in Transfected Cells of High Affinity IgE Receptor,” Nature 337:187-189, 1989.
Blumberg et al., “Antibody-Dependent Cell-Mediated Cytotoxicity Against Cells Infected with the Human immunodeficiency Virus.” Journal of Infectious Diseases 156:878-883, 1987.
Blumberg et al., J. Biol. Chem. 265:14036, 1990.
Bolen et al., Adv. Cancer Res. 57:103-149, 1991.
Boyle et al., “A Dominant Selectable Marker for the Construction of Recombinant Poxviruses,” Gene 65:123-128, 1988.
Breitmeyer et al., J. Immunol. 138:726, 1987.
Brown, Washngton Post, A1 and A22 (Dec. 8, 1995).
Buonocore et al., “Prevention of HIV-1 glycoprotein Transport by Soluble CD4 Retained in the Endoplasmic Reticulum,” Nature 345:625-628, 1990.
Burkhardt et al., Proc. Natl. Acad. Sci. USA 88:7410-7414, 1991.
Clark et al., Science 258:123-126, 1992.
Clark and Ledbetter, Adv. Cancer Res. 52:81-149, 1989.
Clayton et al., Proc. Natl. Acad. Sci. USA 88:5202-5206, 1991.
Clayton et al., “Characterization of Thymus-Derived Lymphocytes Expressing Antigen Receptor Isoforms: Analysis by Gene Transfection,” J. Exp. Med. 172:1243-1253, 1990.
Cline, “Gene Therapy: Current Status and Future Directions,” Schweiz, Med. Wschr. 116:1459-1464, 1986.
Coghlan et al., New Scientist 14-15 (Nov. 25, 1995).
Cooke and Perlmutter, New Biol. 1:66-74, 1989.
Cooke et al., Cell 65:281-291, 1991.
Dalgleish et al., “The CD4(T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus,” Nature 312:763-767, 1984.
Davidson et al., J. Exp. Med. 175:1483-1492, 1992.
Deen et al., “A Soluble Form of CD4(T4) Protein Inhibits AIDS Virus Infection,” Nature 331: 82-84, 1988.
DeFranco, Eur. J. Biochem. 210:381-388, 1992.
Denny et al., “A Chromosome 14 Inversion in a T-Cell Lymphoma is Caused by Site-Specific Recombination Between Immunoglobulin and T-Cell Receptor Loci,” Nature 320:549-551, 1986.
Doyle et al., “Interaction Between CD4 and Class II MHC Molecules Mediates Cell Adhesion,” Nature 330: 256-259, 1987.
Earl et al., “Removal of Cryptic Poxvirus Transcription Termination Signals from the Human Immunodeficiency Virus Type 1 Envelope Gene Enhances . . . ,” Journal of Virology, 64:2448-2451, 1990.
Eiseman and Bolen, Nature 355:78-80, 1992.
Falkner et al., “Escherichia coligpt Gene Provides Dominant Selection for Vaccinia Virus Open Reading Frame Expression Vectors,” Journal of Virology, 62:1849-1854, 1988.
Fanger et al., “Cytotoxicity Mediated by Human Fc Receptors for IgG,” Immunology Today 10: 92-99, 1989.
Fisher et al., “HIV Infection is Blocked in Vitro by Recombinant Soluble CD4,” Nature 331:76-78, 1988.
Fleit et al., Proc. Natl. Acad. Sci. USA 79:3275-3279, 1982.
Frank et al., “Structural Mutations of the T Cell Receptor Chain and Its Role in T Cell Activation,” Science 249: 174-177, 1990.
Friedman et al., “Expression of a Truncated Viral Trans-activator Selectively Impedes Lytic Infection by its Cognate Virus,” Nature 335:452-454, 1988
Gassmann et al., Eur. J. Immunol. 22:283-286, 1992.
Gay et al., “Functional Interaction Between Human T-Cell Protein CD4 and the Major Histocompatibility Complex HLA-DR Antigen,” Nature 328: 626-629, 1987.
Glaichenhaus et al., Cell 64:511-520, 1991.
Gold et al., Nature 345:810-813, 1990.
Goldsmith and Weiss, Proc. Natl. Acad. Sci. USA 84:6879-6883, 1987.
Golstein et al., Immunol. Rev. 68:5-42, 1982.
Gorny et al., Proc. Natl. Acad. Sci. USA 86: 1624,1989.
Goverman et al., “Chimeric Immunoglobulin-T Cell Receptor Prote

Affiliated with

Also associated with

Rating

Redirection of cellular immunity by protein tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Redirection of cellular immunity by protein tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Redirection of cellular immunity by protein tyrosine kinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3950030